Joo Young Na
The Ohio State University Wexner Medical Center(US)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Gut microbiota and health, Probiotics and Fermented Foods
Most-Cited Works
- → Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study(2022)5 cited
- → Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea(2024)3 cited
- → Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial(2025)2 cited
- → supplementary materials 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial(2025)
- → Population pharmacokinetic model of ABL001/CTX‐009 (anti‐VEGF/DLL4) in adult cancer patients with solid tumor(2024)
- → Data from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial(2025)
- → Supplementary Tables 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial(2025)
- → Supplementary Figure 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial(2025)
- → Profiling of endogenous metabolites and changes in intestinal microbiota distribution after GEN-001 (Lactococcus lactis) administration(2024)